10% is Pacific Edge's stated aim in the US market with four different products covering from initial haematuria to monitoring after an operation for bladder cancer for years afterwards.
So who is going to be doing the other 90% when they get that far with that kind of coverage?
And more to the point who else has that kind of coverage to start with?
Bookmarks